Efficacy analysis of <i>ALK</i> inhibitors for treating lung squamous carcinoma patients harboring <i>ALK</i> rearrangement.

导出 OA

翻译打印收藏纠错

第一作者： Jingwen,Wei

第一单位： Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China.;Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China.

作者： Jingwen,Wei ^[1] ; Wei,Sun ^[1] ; Xiaohong,Zeng ^[1] ; Huan,Zhou ^[2] ; Zhengbo,Song ^[1]

作者单位： Postgraduate Training Base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, China.;Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. ^[1] Department of Clinical Trial, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, China. ^[2]

关键词 Alectinib anaplastic lymphoma kinase rearrangement (ALK rearrangement)crizotinib efficacy lung squamous cell carcinoma (lung SCC)

DOI 10.21037/jtd-24-7

PMID 39144336

发布时间 2024-08-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交